ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study - PubMed (original) (raw)

ADAM8 in squamous cell carcinoma of the head and neck: a retrospective study

Valerie Zielinski et al. BMC Cancer. 2012.

Abstract

Background: A disintegrin and metalloproteinase (ADAMs) have been associated with multiple malignancies. ADAMs are involved in cell fusion, cell migration, membrane protein shedding and proteolysis. ADAM8 has been found to be overexpressed in squamous cell carcinomas of the lung. A new study showed that ADAM8 is significantly overexpressed in metastasis of squamous cell carcinomas of the head and neck (HNSCC).

Methods: We determined ADAM8 levels in the serum of 79 HNSCC patients at the time of diagnosis, in 35 patients 3 months after treatment and in 10 patients 1 year after therapy and compared the results to the sera of 31 healthy volunteers. We also constructed tissue microarrays to detect ADAM8 immunohistochemically in 100 patients. The results were correlated with the survival data of the patients to determine the diagnostic and prognostic value.

Results: The data demonstrated that patients with high ADAM8 expression in the tumor have worse survival rates. We found that high ADAM8 serum levels correlated with high ADAM8 expression in tumor samples. Soluble ADAM8 levels did not show any prognostic or diagnostic properties.

Conclusion: In summary ADAM8 expression is a prognostic factor for survival of patients with head and neck squamous cell carcinoma.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Pictures of immunohistochemical staining of ADAM8, 200 × magnification. A and B: ADAM8 negative, C and D: ADAM8 positive.

Figure 2

Figure 2

Kaplan- Meier Curve of immunohistochemistry results divided in two groups (staining < 1 and staining ≥ 1). 0 represents no staining, 1 represents moderate and 2 represents strong staining. Mean IS was calculated from the three samples per patient.

Figure 3

Figure 3

Correlation of immunohistochemistry results and ELISA results. X-Axis: Immunohistochemistry staining. Y-Axis: Elisa results at time of diagnosis.

Figure 4

Figure 4

Boxplots of the serum levels of ADAM8 in all 4 groups. Healthy represents the ADAM8 expression in the healthy control group N = 31, tu00 represents the ADAM8 expression in the serum of tumor patients at the time of diagnosis, N = 79, tu03 represents the ADAM8 expression in the serum of tumor patients 3 months after treatment N = 35, and tu12 represents the ADAM8 expression in the serum of tumor patients 12 months after treatment N = 10.

References

    1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–1154. doi: 10.1056/NEJMra0707975. - DOI - PubMed
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi: 10.3322/canjclin.55.2.74. - DOI - PubMed
    1. Lowy DR, Munger K. Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med. 2010;363(1):82–84. doi: 10.1056/NEJMe1003607. - DOI - PubMed
    1. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007;98(5):621–628. doi: 10.1111/j.1349-7006.2007.00434.x. - DOI - PMC - PubMed
    1. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 2000;16(2):83–87. doi: 10.1016/S0168-9525(99)01926-5. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources